DeepMed Research

ABBVIE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

Pharmacokinetics and Safety of the Co-administration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Healthy Chinese Subjects

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: ABT-450/r/ABT-267
Drug: ABT-333

First Posted Date: 2015-08-28

Last Posted Date: 2015-10-19

Lead Sponsor: AbbVie

Target Recruit Count: 18

Registration Number: NCT02534870

Locations: 🇨🇳
Site Reference ID/Investigator# 137655, Shanghai, China

Study to Investigate Efficacy and Safety of Adalimumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)

Phase 3

Completed

Conditions: Generalized Pustular Psoriasis (GPP)
Adalimumab
Japanese

Interventions: Drug: Adalimumab

First Posted Date: 2015-08-26

Last Posted Date: 2019-01-14

Lead Sponsor: AbbVie

Target Recruit Count: 10

Registration Number: NCT02533375

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABBV-257 in Subjects With Rheumatoid Arthritis

Phase 1

Completed

Conditions: Rheumatoid Arthritis

Interventions: Biological: ABBV-257
Biological: Placebo

First Posted Date: 2015-08-24

Last Posted Date: 2016-03-03

Lead Sponsor: AbbVie

Target Recruit Count: 8

Registration Number: NCT02531178

Locations: 🇩🇪
Site Reference ID/Investigator# 139394, Berlin, Germany

ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-Administered With Ribavirin (RBV) in Treatment Naïve and Treatment Experienced Asian Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Compensated Cirrhosis

Phase 3

Completed

Conditions: Chronic Hepatitis C Virus (HCV)

Interventions: Drug: ABT-450/r/ABT-267
Drug: ABT-333
Drug: ribavirin

First Posted Date: 2015-08-07

Last Posted Date: 2018-10-09

Lead Sponsor: AbbVie

Target Recruit Count: 104

Registration Number: NCT02517528

ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Treatment-Naïve and Treatment-Experienced, Non-Cirrhotic Asian Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection

Phase 3

Completed

Conditions: Hepatitis C Virus (HCV)

Interventions: Drug: ombitasvir/paritaprevir/ritonavir and dasabuvir
Drug: Placebo for ombitasvir/paritaprevir/ritonavir and dasabuvir

First Posted Date: 2015-08-07

Last Posted Date: 2017-10-27

Lead Sponsor: AbbVie

Target Recruit Count: 650

Registration Number: NCT02517515

A Long Term Extension Trial of BI 655066/ABBV-066 (Risankizumab), in Patients With Moderately to Severely Active Crohn's Disease

Phase 2

Completed

Conditions: Crohn Disease

Interventions: Drug: Risankizumab 600 mg IV
Drug: Risankizumab 180 mg SC

First Posted Date: 2015-07-31

Last Posted Date: 2020-04-24

Lead Sponsor: AbbVie

Target Recruit Count: 65

Registration Number: NCT02513459

Locations: 🇧🇪
AZ-Delta /ID# 154983, Roeselare, Belgium
🇺🇸
MGG Group, Inc.Chevy Chase Clinical Research /ID# 155068, Chevy Chase, Maryland, United States
🇪🇸
Hospital Univ de la Princesa /ID# 155065, Madrid, Spain

and more 25 locations

Comparison of Bimatoprost Sustained Release (SR) to Selective Laser Trabeculoplasty (SLT) in Adults With Open-Angle Glaucoma or Ocular Hypertension

Phase 3

Completed

Conditions: Glaucoma, Open-Angle
Ocular Hypertension

Interventions: Drug: Bimatoprost SR
Drug: Sham Bimatoprost SR
Procedure: Selective Laser Trabeculoplasty
Procedure: Sham Selective Laser Trabeculoplasty

First Posted Date: 2015-07-24

Last Posted Date: 2024-05-10

Lead Sponsor: AbbVie

Target Recruit Count: 240

Registration Number: NCT02507687

Locations: 🇺🇸
Wolstan & Goldberg Eye Associates /ID# 235166, Torrance, California, United States
🇺🇸
Trinity Research Group /ID# 234598, Dothan, Alabama, United States
🇺🇸
Houston Eye Associates /ID# 237883, Houston, Texas, United States

and more 92 locations

Impact of Adalimumab on Patient-reported Outcomes in Ulcerative Colitis

Completed

Conditions: Ulcerative Colitis

First Posted Date: 2015-07-23

Last Posted Date: 2021-01-25

Lead Sponsor: AbbVie

Target Recruit Count: 100

Registration Number: NCT02506179

Locations: 🇨🇦
Bellini Medicine Professional /ID# 144241, Brampton, Ontario, Canada
🇨🇦
Oshawa Clinic /ID# 144364, Oshawa, Ontario, Canada
🇨🇦
The Ottawa Hospital /ID# 139392, Ottawa, Ontario, Canada

and more 20 locations

A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/r With or Without Dasabuvir and With or Without Ribavirin in Chronic Hepatitis C Virus Genotype 1 or 4 Infected Adults With Successfully Treated Early Stage Hepatocellular Carcinoma

Phase 3

Terminated

Conditions: Chronic Hepatitis C Infection

Interventions: Drug: ombitasvir/paritaprevir/ritonavir and dasabuvir
Drug: ombitasvir/paritaprevir/ritonavir
Drug: ribavirin

First Posted Date: 2015-07-21

Last Posted Date: 2017-12-12

Lead Sponsor: AbbVie

Target Recruit Count: 3

Registration Number: NCT02504099

A Prospective Non-interventional Multicenter Study to Evaluate the Effectiveness of Adalimumab in Korean Patients With Ulcerative Colitis (UC) and Identify Potential Predictors of Clinical Response in Routine Clinical Practice

Completed

Conditions: Ulcerative Colitis

First Posted Date: 2015-07-16

Last Posted Date: 2019-11-01

Lead Sponsor: AbbVie

Target Recruit Count: 150

Registration Number: NCT02499263

Locations: 🇰🇷
Korea University Anam Hospital /ID# 138446, Seoul, Korea, Republic of
🇰🇷
Kyungpook National Univ Hosp /ID# 153133, Daegu, Daegu Gwang Yeogsi, Korea, Republic of
🇰🇷
St. Vincent's Hospital /ID# 138455, Suwon, Gyeonggido, Korea, Republic of

and more 16 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy